Maastricht Universitair Medisch Centrum
Maastricht Universitair Medisch Centrum
Maastricht, Netherlands12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-09-29 | NCT06943755 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242471 | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT05920356 | |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 3 | 2026-09-08 | NCT07005128 | |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06252649 | |
| Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia | autoimmune hemolytic anemia, warm type | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-31 | NCT04119050 | |
| Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive | Female Contraception | Active, not recruiting | Phase 3 | 2026-06-08 | NCT06394999 | |
| Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-05-07 | NCT05089734 | |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-04-16 | NCT05317416 | |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Arthralgia, Arthritis, Gouty, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Inflammation, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 2 / Phase 3 | 2026-03-11 | NCT05658575 | |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 3 | 2025-12-17 | NCT06211036 | |
| Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) | Bites and Stings, Chemically-Induced Disorders, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, injury, lung disorder, lung neoplasm, neoplasm, poisoning, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 1 | 2025-11-19 | NCT03319940 |